EMA publishes Regulatory Science Strategy to 2025

The European Medicines Agency (EMA) has launched its Regulatory Science Strategy to 2025 to ensure its regulatory work is optimised for the latest innovations in healthcare developments.

The new strategy sets out EMA’s areas of focus for the next five years, including:

  • catalysing the integration of science and technology in medicines development;
  • driving collaborative evidence generation – improving the scientific quality of evaluations;
  • advancing patient-centred access to medicines in partnership with healthcare systems;
  • addressing emerging health threats and availability/therapeutic challenges;
  • enabling and leveraging research and innovation in regulatory science

EMA Executive Director Guido Rasi said:

“This key strategy was developed with the input of a wide range of our stakeholders… I am confident that it will enable us to take a leadership position on new developments, identify the gaps between science and healthcare systems and bring together the various stakeholders needed to bridge those gaps.”

Read the press release launching the strategy here, and the full strategy here.

Tagged with

Published on 2. April 2020 in News, News EU, Press Release